<DOC>
	<DOC>NCT01523990</DOC>
	<brief_summary>A Safety Study to Evaluate the Safety, Tolerability, and Pharmacokinetics in HCV Genotype 1 Infected Patients</brief_summary>
	<brief_title>A Study to Evaluate the Safety, Tolerability, and PK in Healthy Volunteers and HCV Genotype 1 Infected Patients</brief_title>
	<detailed_description>A Phase 1, Randomized, Double-Blind, Placebo-Controlled Study in Healthy East Asian and Caucasian Volunteers to Evaluate the Safety, Tolerability, and Pharmacokinetics Profiles of Single and Multiple Ascending Oral Doses of TG-2349, and Followed by a Dose-Ranging Study in Hepatitis C Genotype 1 Infected Patients.</detailed_description>
	<mesh_term>Hepatitis</mesh_term>
	<mesh_term>Hepatitis C</mesh_term>
	<mesh_term>Hepatitis C, Chronic</mesh_term>
	<criteria>East Asian or Caucasian subjects, male or female, and 18 to 65 years of age inclusive Body mass index (BMI) in the range of 19.0 to 30.0 kg/m2 and body weight ≥ 50 kg inclusive In generally good physical and mental health status on the basis of a medical history review, medical evaluation including vital signs and physical examination, 12lead ECG, and laboratory results at screening For females, one of the following criteria must be fulfilled: 1. At least 1 year post menopausal, or 2. Surgically sterile, or 3. Willing to use a double barrier method [intrauterine device (IUD) plus condom, spermicidal gel plus condom] of contraception from screening until 30 days after the last dose of study drug Males must be willing to use a reliable form of contraception (use of a condom or a partner fulfilling the above criteria) from screening until 30 days after the last dose of study drug Willing to abstain from caffeine or xanthinecontaining beverages, including coffee and tea, alcohol, grapefruit juice, and Seville oranges during the stayonsite period Willing and able to provide written informed consent Positive serological test for IgM antiHAV antibody, HBsAg or antiHCV antibody at screening Positive ELISA test for HIV1 or HIV2 at screening Any abnormal laboratory values at screening: Hemoglobin (Hb) &lt;12.0g/dL for women and &lt;13.0g/dL for men, white blood cell count (WBC) &lt;3,000 cells/mm3, absolute neutrophil count &lt;1,500 cells/mm3, platelet count &lt;100,000 cells/mm3, serum creatinine ≥ 2 mg/dL, ALT or AST levels ≥ 2 xULN, total bilirubin ≥ 1.5 x ULN, INR (International Normalized Ratios for prothrombin time) ≥ 1.5 xULN Any abnormal laboratory values that are considered clinically significant by the Investigator at screening QTcF greater than 450 msec for females and 430 msec for males at screening History of renal, hepatic impairment, stomach or intestinal surgery or resection, malabsorption syndrome History of seizures, epilepsy, cardiovascular, diabetes or cancer (except basal cell carcinoma) History or family history of prolonged QT interval or family history of sudden cardiac death at a young age History of drug allergy or hypersensitivity, especially to sulfa drugs History or evidence of abuse of alcohol, barbiturate, amphetamine, recreational or narcotic drug use within 6 months prior to first dose of study drug administration Prisoners or subjects who are compulsorily detained (involuntarily incarcerated) for treatment of a psychiatric illness, or have any history of suicide attempt or depression Anemia or blood/plasma donation within 30 days prior to first dose of study drug administration Pregnant or breastfeeding Use of tobacco or nicotinecontaining products within 30 days prior to first dose of study drug administration Use of concomitant medication, including herbal remedies, and dietary supplements (except for paracetamol/acetaminophen, ibuprofen and hormonal contraceptives) within 14 days prior to first dose of study drug administration Received any other investigational drug within 30 days prior to first dose of study drug administration</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>65 Years</maximum_age>
	<verification_date>December 2014</verification_date>
</DOC>